AVC 201
Alternative Names: Allo-RevCAR01-T-CD123; AVC-201Latest Information Update: 24 Feb 2026
At a glance
- Originator AvenCell Europe
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 06 Dec 2025 Efficacy and adverse events data from phase I trial in Acute myeloid leukaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)
- 30 Jun 2025 Efficacy data from a phase I trial in Acute myeloid leukaemia released by AvenCell Therapeutics
- 06 Feb 2024 AvenCell plans a phase II trial for cancer